AIRMONY by TBIOM Investor Deck

1. Investor Deck
September 2017

2. TÉCNICAS BIOMÉDICAS PARA LA SALUD (TBIOM)
TBIOM (Técnicas Biomédicas para la
Salud, S.L.) is a top innovative SME, spin-off
from FCTecnics established in September
2015. It is located in Sant Adrià de Besòs,
Barcelona, with 280m2 of space workshop,
storeroom, laboratory and technical office.
TBIOM is currently developing on and
releasing a new medical device (CPAP) for the
treatment of Obstructive Sleep Apnea (OSA).
Current company’s capital is 488.000€, entirely
dedicated to the development and introduction
into the market of the new device. Such capital
has been invested by the founding partners and a
group of crowdfunding investors reached through
CapitalCell platform. TBIOM is the proprietor of
the patent P3280PC00 already obtained in the
domestic market and is also solliciting the PCT to
expand the shelter overseas.
The present document
summarizes several aspects so
essential from the business plan
and finantial forecomings of
TBIOM. The aim in itself is
offering to the investor a loyal
and trusting image and future
perspectives. As TBIOM is such
a developing and expanding
firm also the document is valid
to 30th September 2017. The
data and forecomings currently
enclosed has not to do with
contractual issues.
_____________________
TBIOM SL
c/ Atlàntida 21, 2º 2ª
08930 Sant Adrià Besòs
(Barcelona)
fmartinez@fctecnics.com
www.yourairmony.com
Tested in Android and IOS
with QR Droid and ScanLife

3. What is Sleep Apnea?
The Obstructive Sleep Apnea (OSA) is a
common disorder where breathing is
interrupted or becomes very superficial
during sleep. These interruptions can last
from very few seconds to minutes and can
occur more than 30 times per hour. During
apnea the breathing stops while the person is
sleeping. This happens due to the airway
became narrower or partially blocked.
When the muscles on the upper part of the
throat get relaxed during sleep, the tissues
close up and block the airway. This stop
during breathing is called apnea.
Loud snoring is a warning symptom for OSA.
Snoring is caused by the air that slips through
a narrow or blocked airway. Even though, not
all people that snore suffer from sleep apnea.
Sleep apnea is the triggering effect for
multiple pathologies such as depression,
arrhythmias or hypertension.
In Spain there are between 1 and 2 million
people who suffer from OSA (4% of the
population). 65% of these people are also
overweight.
4% of Spanish people suffer from sleep
apnea. The majority of them are
overweight.
It has also a high incidence on people who
suffer Down Syndrome, Multiple Sclerosis
and athletes who have developed a great
musculature as a consequence of their
activities. The most commonly accepted
treatment by the medical community is
the use of a CPAP device (Continuous
Positive Airway Pressure). ¿What means Sleep Apnea and how
to recognise it?
http://bit.ly/promo_airmony_EN_1
5s
Tested in Android and IOS with QR Droid and ScanLife

4. Current CPAPs
The most common CPAPs in the market
(a 98%), are desktop devices that are
connected to the electricity grid and that
transfer pressurized air from a device
that is located far away from the patient
to the user’s mask through a corrugated
tube. They are typically devices of a
noteworthy size, weight and volume. In
conclusion, devices that are designed to
stay in place on a nightstand.
The current tendency of the market is to
cut down the volume of CPAP devices
as the current size and weight of the
gadget and the fact that it needs a tube
between the equipment and the mask of
the patient supposes an important
inconvenience when bringing the CPAP
around.
CPAP users almost always have to
travel with an extra suitcase for their
device. Also, current CPAPs have to be
plugged into the electrical grid and thus,
reduces the possibility of users to
commute to places where the access to
electricity is limited, such as
transportation (planes, trains) or camping
sites.
Dimensions and the fact that there is a
tube make it difficult for patients to
move around with their device.
Nowadays, there is no CPAP in the
market which works with e-health
technology therefore monitoring
physiologic parameters from the patient,
and doesn’t need a tube.

5. Advantages

6. Presentation Video
Promotional video. Airmony, the air you dream of
http://bit.ly/videoairmonyEN
General video of the company
http://bit.ly/gral_tbiom
● TUBELESS
● PORTABLE
● USB
● SCALABILITY
● SILENT
● MONITOR
● CONNECTIVITY
● WASHABLE
● LOW
CONSUMPTION

7. Patent
We currently own the Spanish patent P3280ES00 of the 7th April 2015 (portable and autonomous air
impeller device that provides assisted ventilation in the treatment of Sleep Apnea Syndrome for people
affected from SAHS and to improve night sleep on elite and/or high performance athletes.) Likewise we
have requested the International PCT that will allow us to protect our technology in the markets where
we want to commercialise our product (Europe and USA).
In our PCT Patent , there are multiple novelties compared to the traditional devices. To emphasise: the
elimination of the corrugated tube, which makes it easier to have proximity sensors on the user’s skin
(suitable to reduce size and also to transform the CPAP into a health manager) and a particular orientation
of the bomb blades, that makes flows and negative dynamic answers possible without inverting the spin
direction.
Nevertheless, the elimination of the exhalation valve that all current CPAPs have in the elbow joint
between the tube and the mask to avoid rebreathing (an effect that is produced if the patient would
breathe again the air that they have previously exhaled) is, without a doubt, the most important advance
that, from a technological point of view, our invention provides and it’s registered in our patent.
The elimination of the exhalation valve is possible thanks to the special design of the blades and the fact that
the exhaled air has to go through a very short distance to expell. This feature allows that the impelled air is
really used by the patient (and not like nowadays, where there is a 75% more air impelled than necessary),
this allows a drastic reduction of the bombing power, perfect to take a step further to the pocket CPAP
since it needs a much smaller motor-
The company is in constant technical evolution following a strategy to protect its intellectual and industrial
property. We are currently working on to obtain new patents for our developments.

8. m-health Connectivity
Simple but effective. Airmony’s Bluetooth
system allows precise sleep monitoring.
Complementary services
Simple but
effective

9. Multiplatform
A web which gives to the specialist the tools to design
interactions, receive parameters and analyze health
data from patients. This allows constant monitoring
and easy medical intervention if needed. There is also
the possibility to maintain a real time medical consult.
An intuitive App for the patient which enables a
continuous communication path with the doctor, to
describe symptoms, ask about diagnostics
Connect several e-health devices. Specially Airmony,
our CPAP.
Information and data secured among the different
system actors.

10. Software
INTEGRATED DATA
Medical monitoring platform
based on a Cloud infrastructure.
The patient can check the
medical data provided by
Airmony as well as from many
other m-health devices
(tensiometer, scales…).
Specialists have access to a
screen with a global vision of
captured data. A colour code
gives the doctor the information
regarding the need of analysing,
revising or changing the
treatment.
NOTIFICATIONS
The doctor can fix parameters
to manage group or individual
notifications according to data.
The doctor or caretaker
receives notifications through
colour codes.
DATA GRAPHICS
The doctor can access in a
visual way to registered data.
The doctor can create a series
of queries simulating medical
consultation. The doctor can
directly communicate with
the patient through text
messages and propose video
consulting.
CLINICAL WORKFLOW
The doctor can create a series
of queries simulating medical
concealling.
The patient can access all
queries through the App.

11. Team
Jaume Palou
CEO
Francesc Martínez
Commercial Director
Miquel Sisteré
Medical Director
Xavier Soucheiron
Advisor
Jordi Petit
Financial Director
Tested in Android and IOS with QR Droid and ScanLife

12. Project development
V.1 App
Software
Constitution
Investment Forum
V.0 Test in
Thailand
Seal of Excellence
V.1 Test
Dr. Estivill
Femindustria
Award
Crowdfunding
closing
Prototype
V.2
Novem
ber
Decem
ber
Crowdfunding
start
Spanish
patent
Congress
poster
Santander
Empenta
Program
Int.
Congress
Praga
Medical Fair
Dusseldorf
Clinical
Trial
V.3
Definitive
Industriali-
zation
SALES
START
Round B
400 k
Pilot test
Dr.
Estivill
Round C
1100 k

13. Market
In Europe and USA there is 100M of people affected by Sleep Apnea (OSA),
around a 15% of the total population. Only a 20% of this people are
diagnosed by specialists and are traditional CPAP users. Between a 5-8%
(1,6M) of this population that are already users have the need for commuting,
for business or leisure, and can’t use a CPAP in transportation such as planes
or where no electrical power system is available, also there is the
inconvenience of travelling with a suitcase dedicated to the CPAP. In Spain, at
the end of 2016 there was more than 400.000 devices in use, which supposes
between a 5-7% of the diagnosed and treated average cases, according to a
study from the Pulmonology and Thoracic Surgery Association.
Worldwide, this means a mature market that is not saturated. Every CPAP
user and Sleep Apnea sufferer that has been already diagnosed knows their
need and values the advantages that Airmony offers from an experience and
therapeutic point of view. It isn’t a saturated market since the annual growth
index is around a 10%. This growth is justified by the current infra diagnosis
that is being eventually overcome due to the raising awareness of the
importance of a good rest for an optimal and healthy life, as well as the need of
replacing the devices due to its obsolescence.
100 M. Affected
20 M. Diagnosed
Fuertes Incrementos
Anuales
Affected

14. User
The main target is a male of 45 to 70 who
suffers from OSA and is diagnosed and
due to professional or leisure reasons has
to come and fro.
Age
Occupation
Status
Nationality
Style
Patient
VALUES
Profession
Health
Travel
Family
Leisure
BIO
45-70
Professor/Business
Married
USA/Europe
Urban
Sleep Apnea

15. Competence
In the top league from CPAPs are involved big multinationals tracing such as PHILIPS RESPIRONICS, firm related to Phillips Healthcare. Another
manufacturing firms of CPAPs to the top range are BREAS and RESMED.
At hand the market follows two trends. In a side the top exigence of devices every time more tiny, lighter and portable. On the other side, the
connectivity linked to the integration of the devices in mobile applications multi plattform ehealth.
BRAND MODEL Db
HOSE
LESS
WEIGHT ECG BLUETOOTH
APP
MULTIPLAT
EHEALTH BATTERY PRICE
TBIOM Airmony 25 YES 125g YES YES YES YES > 2 nights 1499€
BREAS Z1 25 NO 500g NO YES NO NO 1 night 1218€
RESMED Airmini 25 NO 300g NO YES NO NO NO 1750€
PHILIPS
Dreamstation
Go
25 NO 900g NO YES NO YES 1 night 1000€
TRANSCEND MiniCpap 26.6 NO 436g NO NO NO NO 1 night 695€

16. Business Model
Airmony
The main business model of the
company is based on the
commercialization and direct sales
of Airmony devices, through
physical and web distributors.
Nowadays, online distribution,
especially in markets like USA is
gaining market rate. Distribution
through local physical distributors
will be initiated in Europe
(Spain/France/Germany). 4
distributors have already shown
interest.
Software as a Service
E-health multiplatform software
application linked to Airmony
offers telemedicine services to
monitor the different pathologies of
the patients. The user can access his
data, link several mhealth devices
and perform real time video with
specialists. The Danish versions of
this platform has already 150.000
users.
Cloud
Exploitation of the data base
generated. The connection of
Airmony to the Cloud allows
anonymous and automatic
register of data related to
sleep segmented form from
the patients of OSA about
sleep habits and use
conditions.
Accessories
Sales and distribution of
accessories is expected to
overcome the 15% of the
annual business volume of
the company. Transport
cases, cleaning kits,
replacement filters,
replacement batteries,
cables, so on.

17. Canvas model

18. Canvas model

19. Marketing and communication
The marketing and communication strategy of AIRMONY is based on market penetration through various complementary and coadjuvant routes.
In most of the cases, the doctor will be the
one to inform the patient about CPAPs in the
market and to give advice to them.
Airmony has been presented in the National
Congress of Sleep Medicine in Santander
with Dr. Estivill. Presentation from a study
performed by Dr. Estivill about soak up of
dates in Prague International Congress
(October 17th).
Presentations will be performed and we will
be enrolled in different international events
to be promoted in the medical community.
From the advantages and characteristics of
Airmony these traditional marketing actions
will be key considered in the setting of the
product and will be developed in such
several geographical areas in partnership
with the local distributors. As well as is
foreseen the presence in means of
communication and specialised magazines.
The distributor of devices CPAP has special
importance in such specific markets as can be the
European one. It’s defined a leak strategy in the
markets due to the volume and permeability.
The introduction in the market is done through a
selection of agreements with local partners in
every country or countryshire. In very markets,
as USA, online distribution is taking every more
time a big importance as mean of selling. More
and more often there are more web distributors
of CPAP devices.
Every more efforts are made with the vivid
presence in fairs and international events where
medical devices are present.
The come across with the final user is
considered essential to the selling process
and the final decision. The user or future
user of CPAP has the availability to assess
the enhances and chances that different
devices from the market can offer.
A constant changing of tendency from the
competing firms towards a
communication every time more effective
to the user.
Top importance in social nets and media
in the introduction of new devices focused
on big markets.
There are already 30 pre-selling and 90
waiting requests of selling. (3 months hot
promotion).
Doctor Distribution User

20. Sales Forecast
As a first step, needed
inversions are exposed to
the development of I+D
Airmony as well as the
commercial launching that
together with our cash
needs, offers us a vision of
the financial requirements
of the company.
To end up, payments and
expenses forecomings
(P&G) for the next five
years, forecast period to
the launching of the
inversion.
INVESTMENTS
FINANCIAL NEEDS
BALANCE. FORECAST
PAYMENTS &
EXPENSES
ACCOUNT
FORECAST
SALES
FORECAST
COST PER
UNIT
ANALYSIS

21. Investments

22. Cost per unit analysis

23. Sales Forecast

24. Active Balance

25. Passive Balance

26. Payments & Expenses Account

27. Financial Needs

28. Evolution
MAGNITUDES EVOLUTION
EBITDA
DISTRIBUTION MARGIN
GROSS MARGIN

29. Pre-money valuation
The pre-money estimation nowadays is established in 4 Million Euros (September 2017). This is based in the following criteria:
Previous values
In March 2017 we launched the first round with pre-money worth 1.8M. As a result.
Time to market
Currently, we still are in 11 months to launch the product in the European markets. (September 2018)
Technical Risks
We are on disposal of the pre-functional prototype checked in clinical tests and lab tests. Certification process has benn started.
Patent
We have already obtained the Spanish patent with no opposal and currently are taking into account the penetration in the market of PCT to
other markets.
Commercial risks
Is currently developed in the European commercial net through contacts with the main European distributors, working on fairs of the sector
(Medica 2017) and presentations in medical congress (Santander and Praga).
Balance
Between different elements and technical and commercial risks, the scaling of the product, equipment capacity, access time and size of the
market makes necessary a tailored funding will be fitted to the objectives and money invested.

30. Why invest in Airmony?
Sheltered by International Patent
Intellectual property strategy of protection.
A recognised interest from the scientific and
medical community
Active presence in International Congresses.
Constantly growing market
Appealing market with substantial margins of benefit.
Rapid penetration in the market
Counting with existing distributors and online strategy
Innovative Medical Device
Technically advanced in a sector with great multipliers.
Ehealth platform
Completely integrated.
Revolution in the sector
Keeps aside competence products.
Easy and scalable production
Low turnover and management costs

31. Additional Information
What is a sleep apnea and how to recognize it?
http://bit.ly/promo_airmony_EN_15s
Estivill speaks at RTVE about Albert Llovera's sleep on the Dakar
with CPAP Airmony by Tbiom RTVE
http://bit.ly/promo_airmony
Albert Llovera explains his experience with CPAP Airmony in the Dakar
http://bit.ly/llovera_dakar2017
CPAP Airmony for sleep apnea, in Els Diners TV3
http://bit.ly/AirmonyTV3
CPAP Airmony by TBiom in Vallès Visió
http://bit.ly/promo_airmony_EN_15s
Tested in Android and IOS with QR Droid and ScanLife

32. Additional Information
Location
http://bit.ly/locTBIOM
TBIOM website
http://bit.ly/TBIOM
Airmony website
http://bit.ly/AirmonyEN
Airmony blog
http://bit.ly/blogairmonyEN
Recent crowdfunding campaign
Indiegogo
http://bit.ly/Airmony
Facebook
http://bit.ly/TBIOMED
Twitter
http://bit.ly/TbioMedEN
Tested in Android and IOS with QR Droid and ScanLife

33. Facilities

34. Contact Us
www.tbiom.com - www.yourairmony.com